SCHEMBL20208549

SCHEMBL20208549

FC(F)(F)Oc1ccc(-c2cnc3nccn3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.59
KDM4E B2RXH2 1/20 0.56
NPC1 O15118 1/20 0.56
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 1/20 0.56
RAB9A P51151 1/20 0.56
SCN5A Q14524 12/20 0.48
GRM5 P41594 2/20 0.41
SCN1A P35498 1/20 0.41
SCN2A Q99250 1/20 0.41
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
ATP1A1 P05023 1/20 0.39
ATP1B1 P05026 1/20 0.39
ATP1A3 P13637 1/20 0.39
ATP1B2 P14415 1/20 0.39
ATP1A2 P50993 1/20 0.39
ATP1B3 P54709 1/20 0.39
FXYD2 P54710 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20190138 0.81 SCN5A (0.47) DYRK1AKDM4ENPC1ALDH1A1GAA
SCHEMBL20208546 0.79 SCN5A (0.61) DYRK1AKDM4ENPC1ALDH1A1GAA
SCHEMBL20203727 0.79 SCN5A (0.64) KDM4ENPC1ALDH1A1GAAMAPT
SCHEMBL20189412 0.78 GRM5 (0.48) KDM4ENPC1ALDH1A1GAAMAPT
SCHEMBL21436086 0.77 DYRK1A (0.59) DYRK1AKDM4ENPC1ALDH1A1GAA
SCHEMBL20191067 0.76 CYP1A2 (0.50) DYRK1AKDM4ENPC1ALDH1A1GAA
SCHEMBL16474641 0.76 KDM4E (0.40) DYRK1AKDM4ENPC1ALDH1A1GAA
SCHEMBL22130319 0.75 DYRK1A (0.70) DYRK1AKDM4ENPC1ALDH1A1GAA
SCHEMBL360651 0.75 DYRK1A (0.74) DYRK1AKDM4ENPC1ALDH1A1RAB9A
SCHEMBL23572498 0.74 SCN5A (0.52) KDM4ENPC1ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-10-12 US disclosed
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
WO-2018098500-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322790-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B DYRK1A 4493/4885KDM4E 2066/4885NPC1 218/4885
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B DYRK1A 4493/4885KDM4E 2066/4885NPC1 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.